COLDEPORTES 2017 FCC vs Alejandro Ramirez Calderon

7 Sep 2018

In September 2017 COLDEPORTES reported an anti-doping rule violation against the cyclist Alejandro Ramirez Calderon after an Expert Panel of the Salt Lake City Lab concluded unanimously in January 2020 in their Joint Expert Opinion that the Athlete’s hematological profile “highly likely” showed that he used a prohibited substance or a prohibited method: the use of EPO or Blood doping.

This conclusion of the Expert Panel was based on assessment of 9 blood samples, collected in the period between September 2014 and November 2016 reported in the Athlete’s Biological Passport (ABP). 

After notification the Athlete submitted an explanation about the circumstances surrounding the collected samples. However after consideration the Expert Panel rejected the Athlete’s explanations in their second joint report.

Hereafter the Athlete failed to file a statement in his defence nor attended the hearing of the FCC Disciplinary Commission.

The Disciplinaire Commission considered the validity of the proceedings against the Athlete and the evidence regarding the abnormalities in his ABP. The Commission accepts the conclusion of the Expert Panel that the Athlete had used a prohibited subsance or a prohibited method and accordingly that he had committed an anti-doping rule violation.

Therefore the FCC Disciplinairy Commission decides on 7 September 2018 to impose a 4 year period of inelgibility on the Athlete starting on the date of the decision.

COLDEPORTES 2017 FCC vs Julio Alejandro Torres Castañeda

6 Jul 2018

In July 2017 the Colombian Cycling Federation (FCC) has reported an anti-doping rule violation against the cyclist Julio Alejandro Torres Castañeda after his sample tested positive for the prohibited substance Oxandrolone.

After notification the Athlete admitted the violation, waived his right for a hearing and accepted the sanction. In addition he gave substantial assistance to the FCC regarding the person who provided the substance to him. With evidence of the Athlete's communications with this person the FCC could open disciplinary proceedings against this supplier.

The Disciplinary Commission finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that the Athlete has committed an anti-doping rule violation. Further the Commission considers that the Athlete had admitted the violation and provided substantial assistance to the FCC.

Therefore the FCC Disciplinary Commission decides on 6 July 2018 to impose a 3 year period of ineligibility on the Athlete starting on the date of the provisional suspension, i.e. on 14 July 2017.

COLDEPORTES 2017 FECODATLE vs Julieth Paola Caballero Marzola

7 Sep 2018

In March 2018 the Colombian Athletics Federation (FECODATLE) has reported an anti-doping rule violation against the Athlete Julieth Paola Caballero Marzola after her sample tested positive for endogenous 19-norandrosterone (Nandrolone).

After notification a provisional suspension was ordered. The Athlete filed a statement in her defence and she was heard for the FECODATLE Disciplinary Commission.

The Athlete denied the intentional use of the substance and stated that she only had used normal products. She explained that 3 months before the sample collection she had been pregnant but later had a miscarriage. She assumed that hereafter her hormonal disorder could have caused the positive test for endogenous 19-norandrosterone.

The Disciplinairy Commission accepts that the postive test was the result of endogenous production of 19-norandrosterone. Further the Commission considers that the Lab had confirmed that the found substance was endogenous and it had excluded other sources such as genetic doping.

Therefore the Disciplinairy Commissie concludes that No Fault or Negligence had been established and decides on 17 September 2018 to acquit the Athlete and to lift the imposed provisional suspension.

COLDEPORTES 2018 FECODATLE vs Sandra Milena Lemos Rivas

18 Aug 2018

In January 2018 the Colombian Athletics Federation (FECODATLE) has reported anti-doping rule violations against the Athlete Sandra Milena Lemos Rivas after her samples, provided in December 2017 and in March 2018, tested positive for the prohibited substance 19-norandrosterone (Nandrolone).

After notification a provisional suspension was ordered. The Athlete filed a statement in her defence and she was heard for the FECODATLE Disciplinary Commission.

The Disciplinary Commission accepts the Athlete's explanation that the violation was not intentional and established how it entered her system during bodybuilding out-of-competition.

The Athlete acknowledged that she was seeking to improve her performances and had used Deca recommended by people from her bodybuilding gym. Before using she accepted their reassurances that the product was no doping.

Considering No Significant Fault or Negligence the Disciplinary Commission decides on 18 August 2018 to impose a 2 year period of ineligibility on the Athlete starting on the date of the first sample collection, i.e. 27 October 2017.

COLDEPORTES 2019 FCFC vs Carlos Andres Valencia

10 Apr 2019

In December 2018 the Colombian Bodybuilding & Fitness Federation (FCFC) has reported an anti-doping rule violation against the bodybuilder Carlos Andres Valencia after his sample tested positive for the prohibited substances Clenbuterol and Furosemide.

After notification the Athlete admitted the violation, waived his right for a hearing and accepted the sanction proposed by the FCFC.

The Disciplinary Commission of the FCFC considered the Athlete's degree of fault and that he has admitted the violation. Therefore the Disciplinary Commission decides to impose a 24 month period of ineligibility on the Athlete.

COLDEPORTES 2019 FCFC vs Ingrid Vanesa Tique Rodriguez

12 Apr 2019

In December 2018 the Colombian Bodybuilding & Fitness Federation (FCFC) has reported an anti-doping rule violation against the bodybuilder Ingrid Vanesa Tique Rodriguez after her sample tested positive for the prohibited substances Clenbuterol and Oxandrolone.

After notification the Athlete admitted the violation, waived her right for a hearing and accepted the sanction proposed by the FCFC.

The Disciplinary Commission of the FCFC considered the Athlete's degree of fault and that she has admitted the violation. Therefore the Disciplinary Commission decides to impose a 24 month period of ineligibility on the Athlete.

COLDEPORTES 2019 FCFC vs Diana Katherine Cardozo Ramirez

15 Apr 2019

In December 2018 the Colombian Bodybuilding & Fitness Federation (FCFC) has reported an anti-doping rule violation against the bodybuilder Diana Katherine Cardozo Ramirez after her sample tested positive for the prohibited substances Clomifene and Oxandrolone.

After notification the Athlete admitted the violation, waived her right for a hearing and accepted the sanction proposed by the FCFC.

The Disciplinary Commission of the FCFC considers the Athlete's degree of fault and that she has admitted the violation. Therefore the Disciplinary Commission decides to impose a 12 month period of ineligibility on the Athlete.

COLDEPORTES 2019 FCFC vs Hugo Arnulfo Sanchez Itaz

12 Apr 2019

In January 2019 the Colombian Bodybuilding & Fitness Federation (FCFC) has reported an anti-doping rule violation against the bodybuilder Hugo Arnulfo Sanchez Itaz after his sample tested positive for multiple prohibited substances:

  • 1-androstenediol
  • 1-Testosterone
  • Androstatrienedione
  • Boldenone
  • Clenbuterol
  • Dehydrochlormethyltestosterone
  • Stanozolol

After notification the Athlete admitted the violation, waived his right for a hearing and accepted the sanction proposed by the FCFC.

The Disciplinary Commission of the FCFC considers the Athlete's reputation and that he had admitted the violation. Therefore the Disciplinary Commission decides to impose a 36 month period of ineligibility on the Athlete.

The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety

17 Sep 2012

The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety / Rhonda Orr, Maria Fiatarone Singh. - (Drugs 64 (2004) 7; p. 725-750)

  • PMID: 15025546
  • DOI: 10.2165/00003495-200464070-00004


Abstract

There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty associated with loss of muscle tissue in aging (sarcopenia).

One such agent is the anabolic androgenic steroid (AAS) oxandrolone, which has been used in such clinical situations as HIV-related muscle wasting, severe burn injury, trauma following major surgery, neuromuscular disorders and alcoholic hepatitis for over 30 years. In the US, oxandrolone is the only AAS that is US FDA-approved for restitution of weight loss after severe trauma, major surgery or infections, malnutrition due to alcoholic cirrhosis, and Duchenne's or Becker's muscular dystrophy.

Our review of the use of oxandrolone in the treatment of catabolic disorders, HIV and AIDS-related wasting, neuromuscular and other disorders provides strong evidence of its clinical efficacy. Improvements in body composition, muscle strength and function, status of underlying disease or recovery from acute catabolic injury and nutritional status are significant in the vast majority of well designed trials. However, oxandrolone has not yet been studied in sarcopenia.

Unlike other orally administered C17alpha-alkylated AASs, the novel chemical configuration of oxandrolone confers a resistance to liver metabolism as well as marked anabolic activity. In addition, oxandrolone appears not to exhibit the serious hepatotoxic effects (jaundice, cholestatic hepatitis, peliosis hepatis, hyperplasias and neoplasms) attributed to the C17alpha-alkylated AASs. Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level.

However, optimal risk:benefit ratios for oxandrolone and other agents in its class will need to be refined before widespread clinical acceptance of AASs as a therapeutic option in sarcopenia and other chronic wasting conditions.

Moral disengagement and associated processes in performance-enhancing drug use: a national qualitative investigation

10 Jan 2014

Moral disengagement and associated processes in performance-enhancing drug use : a national qualitative investigation / Ian D Boardley, Jonathan Grix, Andrew James Dewar. - (Journal of Sports Sciences 32 (2014) 9 (7 April); p. 836-844)

  • PMID: 24405120
  • DOI: 10.1080/02640414.2013.862842


Abstract

This study investigated psychosocial processes associated with avoidance of health- and morality-based deterrents to performance-enhancing drug (PED) use. In-depth semi-structured interviews were conducted with 64 English male bodybuilders with experience of doping. Resultant data were content analysed deductively using definitions for the eight mechanisms of moral disengagement (MD; Bandura, A. (1991). Social cognitive theory of moral thought and action. In W. M. Kurtines & J. L. Gewirtz (Eds.), Handbook of moral behavior and development: Theory research and applications (pp. 71-129). Hillsdale, NJ: Lawrence Erlbaum Associates.), and three further themes from Boardley and Grix (2013. Doping in bodybuilders: A qualitative investigation of facilitative psychosocial processes. Qualitative Research in Sport, Exercise, and Health. Advance online publication, doi 10.1080/2159676X.2013.766809). These analyses evidenced six MD mechanisms, and all three of the themes from Boardley and Grix (2013. Doping in bodybuilders: A qualitative investigation of facilitative psychosocial processes. Qualitative Research in Sport, Exercise, and Health. Advance online publication). Subsequent frequency analyses revealed six of the eight MD mechanisms, and two of the three additional themes, were common across the sample. Overall, the findings suggest MD may help athletes circumvent health- and morality-based deterrents to doping, describe a process linking supplement and PED use and detail how some athletes may actively avoid social censure for doping by only discussing PED use with other PED users from within their training environment.

Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin